Loading clinical trials...
Loading clinical trials...
The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatien...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Neurocrine Biosciences
NCT07565428 · Negative Symptoms of Schizophrenia
NCT07645443 · Early Onset Psychosis, First Psychotic Episode Within the Last 5 Years, and more
NCT07105098 · Schizophrenia
NCT06894212 · Schizophrenia
NCT06003036 · Schizophrenia, Schizoaffective Disorder
Neurocrine Clinical Site
Kazanlak
Neurocrine Clinical Site
Pazardzhik
Neurocrine Clinical Site
Targovishte
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions